Company profile
Normunity AccelCo, Inc.
Privately held: no public share price (Trial-sponsor entity for Normunity's NRM-823 programme. The AccelCo-to-Normunity link is inferred from the trial-sponsor listing rather than a corporate filing, but Normunity itself is privately held (Series B, Jan 2025), so private holds either way. Parent: Normunity, Inc. (private). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.healthpartners.com/institute/research/studies/a-phase-1a-1b-study-of-nrm-823-as-monotherapy-and-in-combination-with-immune-checkpoint-inhibition-in-participants-with-locally-advanced-or-metastatic-refractory-solid-tumors/]) · United States
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Bispecific T-cell engager (BiTE-format monoclonal antibody)Multispecific antibody | Non-Small Cell Lung Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.